Value of CA 15:3 in the follow-up of breast cancer patients.

CA 15:3, a new tumour marker detectable by two monoclonal antibodies (115 D 8 and DF 3), was measured by an immunoradiometric technique on the ELSA solid phase. Sixteen percent of patients with localized breast cancer had CA 15:3 levels greater than 25 U ml-1, and levels increased with tumour size....

Descripción completa

Detalles Bibliográficos
Autores principales: Pons-Anicet, D. M., Krebs, B. P., Mira, R., Namer, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001716/
https://www.ncbi.nlm.nih.gov/pubmed/3475109

Ejemplares similares

Ejemplares similares